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There is little question that the study of recovering lymphoid cell populations 
following bone marrow transplantation is important to the understanding of the 
biology of transplantation.  With a  full understanding of the types of cells, their 
sequence of appearance, and their relationship to such clinical situations as graft- 
vs.-host disease (GVHD) ~ and graft rejection, it is likely that it will be possible to 
significantly  improve  the  therapeutic  efficacy of  marrow  transplantation.  In 
addition,  identifying the  recovering cells  is  the  first  step  to establishing  their 
functional role in the recovering immune system. 
The availability of monoclonal antibodies (mAb) and flow cytometry has made 
it possible to easily and rapidly determine the phenotype of blood cells. However, 
it has become clear that studies of single surface antigens are extremely limited 
in  their ability  to define  cell  types.  This study  was  undertaken  to  develop as 
complete a  description as possible of the  recovering lymphoid cell types after 
transplantation, using a large panel of mAb and multiparameter flow cytometry. 
We summarize  here results  of over 400  dual-fluorescence analyses done on 
four  marrow  transplant  patients  during  the  early stages  of marrow  recovery. 
The  data  for  the  first  90  d  after  transplantation  is  presented.  Three  of the 
patients  received T  cell-depleted marrow  from an  HLA-matched donor.  The 
fourth received untreated  marrow  from an  identical  twin.  The comparison of 
these  four  patients  allows  us  to  study  the  possible  effects of marrow  T  cell 
depletion on the early recovering immune system. 
Our results indicate that the pattern of recovery of lymphoid cells is similar in 
each of the patients. Six major cell types account for >90% of the lymphoid cells 
in  these  patients;  the  major differences between  patients  occur in  the relative 
numbers of the cells and their time of appearance. In addition to the six major 
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cell types, a  number  of subsets can be identified that are much more variable  in 
their  appearance  and  numbers,  and a  few rare  cell  types can be identified  that 
are present in some patients in small numbers. 
Methods 
Patients.  All four patients were transplanted for acute leukemia: patient  151, a 22-yr- 
old female, for acute myelogenous leukemia in remission; patient  152, a  13-yr-old male, 
for acute  myelogenous leukemia  in  relapse;  patient  153,  a  34-yr-old female,  for acute 
lymphoblastic leukemia in relapse; and patient  155, a  3-yr-old female, for acute lympho- 
blastic leukemia in remission. All patients received pretransplant conditioning consisting 
of cytosine  arabinoside  500  mg]m~/day by  continuous  intravenous  infusion  for  7  d, 
followed by total body irradiation  either  with  1,040 rad (151) or  1,200 rad (152,  153, 
and  155) midline dose in six fractions over three consecutive days at 5 rad/min, and 60 
mg/kg/day  cyclophosphanfide  for  2  d.  Donors  were  all  HLA-  and  MLC-compatible 
siblings. Patient  155 received marrow from her identical twin. 
Marrow  was harvested  by standard  methods.  Marrow  transplanted  to patients  151, 
152, and  153  was treated  with  mAb (anti-Leu-1) and complement to remove donor T 
cells.  Briefly, marrow leukocytes were isolated on an IBM 2991  cell washer, and mono- 
nuclear cells were harvested on a Ficoll-Hypaque (Pharmacia Fine Chemicals, Piscataway, 
N  J)  cushion.  These  cells  were incubated  with  a  saturating  concentration of anti-Leu-1 
mAb for 30 rain at 4°C, followed by incubation with baby rabbit complement (Pel-Freez, 
Rogers, AR) for 45 rain at room temperature.  This treatment was repeated three times. 
Total  residual  T  cells,  defined  as  the  number  of  Leu-4  +  cells,  determined  on  the 
fluorescence-activated cell sorter (FACS), ranged from <0.1%  to 0.9% of marrow cells. 
The total dose of treated marrow cells infused in the patients ranged from 0.75 x  108 to 
1.5 X  l0 s nucleated cells/kg. 
Patients  151,  152,  and  153  received  posttransplant  intravenous  methotrexate  10 
mg/m  ~ on days +1, +3, +6, and +11, for GVHD prophylaxis. Patients 151,153, and 155 
showed no evidence of GVHD. Patient  152 had grade II acute GVHD developing at day 
+48. He received an intravenous infusion ofanti-Leu-1 mAb (Becton-Dickinson, Mountain 
View, CA), in doses sufficient to saturate all peripheral-blood T  cell-binding sites,  for 5 
d  with resolution  of the GVHD by day +55, and no subsequent  recurrence of GVHD. 
Patients 151 and 155 are alive and well at 6 and 4 mo posttransplant, respectively. Patient 
152 died of idiopathic interstitial pneumonitis on day +95. Patient  153 died of recurrent 
leukemia and sepsis on day +143. 
Cell  Preparation.  Heparinized  blood  samples  were  obtained  from  the  patients  at 
various intervals beginning as soon as lymphocytes were identified in the blood. Initially, 
samples were obtained approximately every 2 wk, the intervals stretching to  1 mo after 
the first  30-60 d. The blood was mixed with  JA vol of Lymphocyte Separator  Reagent 
(Technicon Instruments  Corp.,  Tarrytown,  NY), and  incubated at  37°C  on a  rotating 
platform for 1 h. This was done to allow the monocytes and polymorphonuclear leukocytes 
to phagocytize iron  particles,  improving their  depletion  during  the  subsequent  density 
gradient separation step. The blood was then diluted with two vol of Hank's balanced salt 
solution and centrifuged over a cushion of Ficoll-Paque (Pharmacia Fine Chemicals). The 
mononuclear cell interface was harvested,  the cells washed,  counted, and aliquoted  for 
labeling. 
Antibodies.  The  majority  of the  antibodies  were  obtained  from  Becton  Dickinson. 
They  were  mAb  conjugated  either  to  fluorescein  (FL)  or  phycoerythrin  (PE)  (1)  as 
indicated in Table I. In some cases, the antibodies were conjugated to biotin. Other mAb 
included: biotinylated B 1, and unconjugated B2, both from Coulter Immunology (Hialeah, 
FL). 
Conventional antibodies  used in  these  studies  included:  FL-F(ab')2 fraction of rabbit 
anti-human IgG, IgM, and IgD; these antibodies were obtained from Cappel Laboratories 
(Cochranville, PA); F(ab')2 fraction of rabbit anti-human K and X light chains; these were 
obtained  from  Accurate  Chemical  and  Scientific  Company  (Westbury,  NY)  as  intact AULT  ET  AL.  1485 
TABLE  I 
mAb Used in This Study 
Name  Similar*  Normal cell types labeled  References 
HLE- 1  Leukocytes  2 
Leu-M3  Monocytes  3 
Leu-l  T1  T cells and some B cells  4 
Leu-2  T8  T cells (cytotoxic/suppressor)  4, 5 
Leu-3  T4  T cells (helper/inducer)  4, 5 
Leu-4  T3  T cells  4 
Leu-5  T11  T and NK cells (SRBC receptor)  6 
Leu-6  T6  Thymocytes  --* 
Leu-7  NK and some T cells  7 
Leu-8  Some T cells  8 
Leu-9  T and NK cells  9 
Leu-10  B and activated T cells (HLA-DC)  10 
Leu-11  NK cells  11 
Leu-12  B cells  __5 
Leu-14  B cells  __5 
Leu-15  NK and some T cells  12 
HLA-DR  1A  B and activated NK and T cells  13 
CALLA  J5  Early B cells  14 
B1  B cells  15 
B2  B cells  16 
* Similar  antibodies in  the  nomenclature of OKT  (Ortho  Diagnostic 
Systems, Raritan, NJ) or Coulter Immunology (Hialeah, FL). 
5 Specific descriptions of these antibodies not yet published. 
immunoglobulin,  and the F(ab')2 fractions prepared in our laboratory by pepsin digestion 
according to standard methods; FL-goat anti-rabbit IgG, obtained from Cappel Labo- 
ratories; FL-goat anti-mouse IgM (Becton Dickinson) was used as a second antibody for 
the B2 labeling. 
The biotinylated  antibodies were used in combination with either PE- or FL-conjugated 
avidin (Becton Dickinson). 
Cell Labeling.  The labeling protocol followed for each patient is shown in Table II. 
25 pairs of mAb were chosen. Additional studies using other antibodies were added in 
order to further characterize some cell types as described below. 
The commercial mAb were used according to manufacturer's directions, 5 #1 antibody 
solution being used to label 106 cells. Double labeling was accomplished in a single step, 
by addition of both mAb. The cells were incubated on ice for 30 rain with the antibodies, 
washed twice with ice cold phosphate buffered saline, then fixed with 1% paraformalde- 
hyde.  During labeling, the  cells were carefully protected from light, and subsequently 
stored at 4°C in the dark before analysis. 
Cells labeled with biotinylated antibodies were washed three times, then incubated with 
PE-avidin (5  tA) or  FL-avidin (2.5  #1), washed twice,  and fixed.  Cells labeled with  B2 
antibody were incubated with FL-anti-mouse IgM (2.5 #l) as a second step reagent, then 
washed and fixed. 
Conventional antibodies were  used  at  concentrations previously determined to  be 
saturating on normal blood lymphocytes, usually ~50 ~g of antibody protein being used 
to label 106 cells. 
In the case of the Ig light chain labeling, an indirect method was used in which the cells 
were first incubated as described above with the anti-light chain antibodies, followed by 
three washes, a  second identical incubation with FL-goat anti-rabbit IgG, three more 
washes, and fixation. 
Conditions for Flow Cytometric Analysis.  A  Becton Dickinson FACS 440 was used for 
analysis and sorting of the specimens. The instrument was operated with an Argon ion 1486  CELL  PHENOTYPING AFTER  MARROW  TRANSPLANTATION 
TABLE  II 
Labeling Protocol 
FL ANTIBODY  PE-ANT1BODY 
1.  HLE  Leu-M3 
2.  Leu-4  Leu-1 
3.  Leu-4  Leu-5 
4.  Leu-9  Leu-4 
5.  Leu-9  Leu-1 
6.  Leu-6  Leu-5 
7.  Leu-2  Leu-3 
8.  Leu-9  Leu-2 
9.  Leu-9  Leu-3 
10.  HLA-DR  Leu-2 
11.  HLA-DR  Leu-3 
12.  Leu-4  Leu-7 
13.  Leu-11  Leu-7 
14.  Leu-4  Leu-15 
15.  Leu-9  Leu-15 
16.  Leu-5  Leu-15 
17.  Leu-7  Leu-15 
18.  Leu-I 1  Leu-15 
19.  Leu-2  Leu-15 
20.  Leu-7  Leu-2 
21.  Leu-9  Leu-7 
22.  Leu-11  Leu-2 
23.  Leu-11  Leu-4 
24.  Leu-4  Leu-2 
25.  Leu-12  Leu~l 
laser at 488 nm and 300 mW. Alignment and calibration was performed using glutaral- 
dehyde-fixed chicken erythrocytes. The  fluorescence sensitivity of the  instrument was 
checked,  and  the  photomultiplier voltage  adjusted  to  place  the  chicken  erythrocyte 
standards in the same position for each analysis.  10  4  logarithmic amplification was used 
for both FL and PE fluorescence. FL and PE fluorescence was separated using a 580 nm 
long pass dichroic mirror as a  beam splitter.  FL fluorescence was measured through a 
530 _+  30 nm band pass filter. PE fluorescence was measured through a  580 +  25 nm 
band pass filter. 
The first sample of each run was labeled with FL-HLE antibody, which labels all blood 
leukocytes,  and  PE-Leu-M3,  which  labels  monocytes.  This  sample  was  used  for  two 
purposes.  First, a  gate was set on the forward and right-angle light scatter parameters, 
which included all of the brightly HLE-labeled lymphocytes, excluding as much as possible 
the unlabeled erythrocytes and the Leu-M3-1abeled monocytes. Since these samples were 
monocyte depleted, there was seldom a significant  number of monocytes (<3 %). Similarly, 
the few polymorphonuclear leukocytes were identified by lower levels of HLE labeling, 
and these were easily excluded by gating on right-angle light scatter. Second, this sample 
was used to adjust the setting of the instrument's fluorescence-compensation  network to 
eliminate a small amount of spillage of FL fluorescence into the PE channel. When these 
adjustments were made, a dual-parameter (FL vs. PE) histogram was obtained to confirm 
the lack of FL fluorescence in the PE channel and to accurately measure the number of 
erythrocytes that had been included in the light-scatter gates.  Although monocytes and 
polymorphonuclear  leukocytes were rigidly excluded from our data using these methods, 
there were  variable numbers of erythrocytes (5-50%) included in our gates.  This was 
intentional, so as not to exclude any small lymphocytes from analysis. In addition, in some 
cases there were large numbers of nucleated erythrocytes circulating in these patients, AULT  ET  AL.  1487 
which were, of necessity, included in our gates. As described below, our data was corrected 
for the presence of these cells. 
All of the  samples  from a  single  patient  were  then  analyzed sequentially,  collecting 
dual-parameter  histograms of FL and  PE fluorescence data  from 20,000-50,000  cells. 
These  histograms  were  stored  and  subsequently  analyzed  using  a  Becton  Dickinson 
Consort  40  computer  and  software.  In  some  cases,  list  mode  data  was  taken  without 
gating, to confirm that all cells of interest were being included in the gates. This was done 
primarily when  small  numbers of cells of particular  interest  (such as Leu-6  + cells) were 
detected. The histograms presented here display FL fluorescence on the abscissa and PE 
fluorescence  on  the  ordinate.  Contour  lines  are  drawn  on  the  histograms  at  levels 
corresponding to 2, 4 ....  10, 20 ....  90% of the highest peak in the histogram. 
Data  Reduction.  The  sets  of dual-parameter  histograms  were  analyzed  by  placing 
windows around resolved cell types of interest and expressing the number of cells within 
the window as a percent of the total cells within the histogram. This percentage was then 
normalized to the total percentage of lymphocytes contained within the gates, as deter- 
mined  by HLEolabeling described above.  In this  way, unlabeled  erythrocytes were ex- 
cluded from the analysis. The absolute number of circulating lymphocytes was calculated 
from the patient's  total  white  count and differential  count done on a  Wright-Giemsa- 
stained smear the same day. The absolute number of cells of each type was estimated by 
multiplying the percentage obtained above by the absolute lymphocyte count. 
Control samples labeled with FL- and PE-conjugated mouse IgG1 mAb confirmed that, 
in the regions occupied by labeled cells, there was insignificant nonspecific labeling (< 1%). 
The placement of windows around cell populations is somewhat subjective. In order to 
estimate the accuracy of our data, we made every effort to obtain at least two estimates 
of the fraction of each cell type of interest.  In most cases, it was possible to identify the 
same cell population  in at  least  two different histograms.  The mean  variation  in these 
duplicate estimates for 40 different analyses was 11.0 +  2.1% of the mean. 
DNA Polymorphism  and Ig Gene Analysis.  Before transplantation,  blood was obtained 
from patients and donors to screen for DNA sequence polymorphisms that could distin- 
guish the patient or donor origin of the cells after transplant, as described previously (17). 
Briefly, 5-16 ttg of DNA from blood leukocytes were digested  to completion with the 
appropriate restriction  endonuclease,  fractionated by agarose gel electrophoresis,  trans- 
ferred to nitrocellulose filters, and then hybridized with the corresponding radiolabeled 
probe.  Patient  155 was an identical  twin, and was not tested.  Blood was obtained after 
transplantation as soon as peripheral blood leukocyte counts were 500-1,000 cells/mm s, 
and again at least one more time when peripheral blood counts had recovered. 
Donor, patient (pre- and posttransplant),  and posttransplant-sorted  Leu-lB cells from 
patient 151 were analyzed for clonal somatic rearrangements of the Ig genes, using probes 
for the heavy chain switch region (JH), K chain constant region (C,), and X chain constant 
region (Cx), as previously described (18). 
Natural Killer (NK) Cell Functional Assay.  NK cell function was assayed in a standard 
4-h  51Cr-release  assay,  using K-562  cells  as  the  target.  This  assay was  done exactly as 
described previously (19). 
Results 
Definition  of Cell  Types.  The  following cell  types  were  identified  in  all  four 
patients and are discussed in detail below. The manner in which these cells were 
identified for purposes of quantitation is described here: Th cells were identified 
by the presence of Leu-3 but not Leu-2. Ts cells were identified by the presence 
of bright  Leu-2 and  Leu-4 but not Leu-3 or Leu-11.  B  cells were identified  by 
the presence of Leu-12  and absence  of Leu-1.  Leu-1  B  cells were identified  by 
the presence of Leu- 12 and low levels of Leu- 1. Their identity was confirmed in 
detail as described below. Total NK cells were identified by the presence of Leu- 1488  CELL  PHENOTYPING  AFTER  MARROW  TRANSPLANTATION 
11  and Leu-15  but  not  Leu-4.  Leu-2-bearing NK cells  were identified by the 
presence of Leu-11 and low levels of Leu-2 but not Leu-4. 
Table III summarizes the phenotype of each of these cell types. Each of these 
cell types could be further subdivided on the basis of other studies, as described 
below. Figs.  1-4 show illustrative examples of dual-parameter histograms taken 
from patient 151.  All of the patients showed similar labeling patterns for each 
of the cell types described here. The only differences noted between the four 
patients were quantitative in nature. In particular, patient 155, who had received 
untreated marrow from an  identical twin donor, showed the same pattern  of 
recovering cell types as the other three patients. 
Th  Cells.  In  each patient, cells having the phenotype of normal blood Th 
cells appeared between days 10 and 20. These cells are best illustrated in Fig. 1, 
C and D.  Fig. 1 C shows the presence of Leu-3 but not Leu-2 on these cells, and 
D shows the same cells as Leu-2- and Leu-4  +. Fig.  1  A illustrates the coordinate 
expression of both Leu-1 and Leu-4 that was observed in all patients. Additional 
markers present on these cells included Leu-5 and Leu-9. Fig.  1  B illustrates the 
expression  of Leu-5 on  all of the  Leu-4  + cells.  Labeling with  Leu-9  was  less 
intense  than  that  seen  on  the  NK  cell  subsets,  as  described  below  (data  not 
shown). Several other markers were variably expressed on these cells,  including 
Leu-15, Leu-7, Leu-8, and HLA-DR. Patient 151  had particularly strong Leu- 
15  expression  on all of her T  and NK cells;  however, the other patients had 
variable expression of this antigen. Leu-7, Leu-8, Leu-10, and HLA-DR were 
even more variable in their expression, even in sequential studies on the same 
patient. 
Ts Cells.  Each of the patients also began to have cells with the phenotype of 
normal Ts cells  between days  10  and 20.  These cells  were initially present  in 
numbers comparable to the Th cells. They are illustrated in Fig. 2, C and D. Fig. 
1 D shows them as Leu-2-bright cells  also expressing Leu-4.  In C they are not 
clearly resolved from the larger population of Leu-2-dim cells discussed below. 
It is,  however,  clear from C  that they do not express  Leu-3.  Other  markers 
expressed by these cells included Leu-1, Leu-5, and Leu-9, the latter in quantities 
less than the NK cells,  and comparable to the Th cells.  The expression of Leu- 
15,  Leu-7, Leu-8, Leu-10, and HLA-DR was also variable on these cells.  They 
were Leu-11- (Fig. 3, A).  Fig.  1, D  is of particular importance, since it clearly 
illustrates that the Leu-2-bright cells are a  phenotype distinct from the Leu-2- 
TABLE  III 
Phenotype of Major Lymphoid Cell Populations After Transplantation 
Cell  type  Leu-4  Leu-1  Leu-5  Leu-2  Leu-3  Leu-11  Leu-12 
Ts  +  +  +  +  -  -  - 
Th  +  +  +  -  +  -  - 
Leu-1  ÷  B  -  dim  ....  + 
B  ......  + 
NK-I  -  -  +  -  -  +  - 
NK-II  -  -  +  dim  -  +  - 64, 
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FIGURE  1.  Analysis of T  cell subsets after transplantation. (A) Dual-parameter histogram of 
Leu-4  (horizontal) vs.  Leu-1  (vertical).  Both  are  pan-T antibodies, and  the  population of 
mature T  cells is labeled by both. An additional population of cells having dim Leu-I labeling 
but no Leu-4 labeling is seen. (B) Leu-4 (horizontal) vs. Leu-5 (vertical). Again, the mature T 
cells are labeled with both antibodies. In addition, there is a large population of cells labeling 
only with  Leu-5.  (C)  Leu-2 (horizontal) vs.  Leu-3  (vertical). The population of Th  cells is 
clearly shown labeled with Leu-3 but not Leu-2. The cells labeled with Leu-2 consist of two 
populations, one dimly labeled, and one brightly labeled, as can be seen more clearly in D. (D) 
Leu-4 (horizontal) vs.  Leu-2 (vertical). The population of cells that are brightly labeled with 
Leu-2 are also labeled with Leu-4, and are the Ts cells. The cells dimly labeled with Leu-2 do 
not bear Leu-4, and are a subset of NK cells.  An additional population of cells are labeled by 
Leu-4 but not Leu-2; these are the Leu-3-bearing Th cells. 
dim cells. There is no evidence for any transitional cells between the Leu-2-dim, 
Leu-4- cells and the Leu-2-bright, Leu-4  + cells. In none of the patients were any 
significant numbers of cells detected bearing both Leu-2 and Leu-3. 
B  Cells.  B  cells appeared  in three of the patients between days 20 and  30. 
Patient 152 failed to develop any detectable B cells. In all three of the patients, 
there were two distinct phenotypes of B cells detectable. 
Fig. 2 illustrates data from patient  151  at a  time when she clearly had both B 
cell  subtypes.  One  type of B  cells  had  markers  identical  with  the  majority of 
normal blood B cells. These are illustrated in Fig. 2, A and C. In A, they are seen 
as Leu-l-, Leu-12  + cells. In C it can be seen that they are Leu-l-, B1 +, although 
the amount of B1  they express is not as great as that of the other B cell subtype. 
The population seen in Fig. 2A that expresses both Leu-12 and low levels of 
Leu-1  is of particular interest.  In all three of the patients (151,  153, and  155) 1490  CELL  PHENOTYPING  AFTER  MARROW  TRANSPLANTATION 
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FIGURE  2.  Analysis of B cells after transplantation. (A) Leu-12 (horizontal) vs. Leu-1  (verti- 
cal). The T  cells are brightly Leu-1 ÷, and are Leu-12-.  There is a  large population of cells 
that are dimly Leu-1 ÷ and strongly Leu-12  +. These are the Leu-1 B cells described in the text. 
There is a  smaller population of cells that are Leu-1- and Leu-12 +, these are conventional B 
cells. (B) HLA-DR (horizontal) vs.  Leu-1  (vertical). The T  cells express variable amounts of 
HLA-DR, whereas the Leu-1  B cells are brightly HLA-DR  ÷. The Leu-1- cells have variable 
amounts  of HLA-DR,  corresponding to  HLA-DR  expression on  conventional B  cells, and 
some N K Cells. (C) B 1 (horizontal) and Leu-1 (vertical). The Leu-1 B cell population is strongly 
B1 ÷, whereas the conventional B cells express lower amounts of B1. (D) IgD (horizontal) vs. 
Leu-I (vertical). Similar studies (not shown) have demonstrated that both the conventional B 
cells and the Leu-1  B cells express IgM and IgD, but not IgG. They also both contain cells 
expressing K and cells expressing X light chains. The  Leu-1  B  cells express more IgM  than 
conventional B cells. 
D 
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who developed significant numbers of B cells,  these were the predominant cell 
type. We will refer to these as Leu-1 B cells. They are also seen in Fig. 2C, where 
they are strongly B 1  +. Fig. 1  A also illustrates these cells,  where they are seen as 
Leu-l-dim, Leu-4-.  Fig.  2, B and D  illustrate the expression of HLA-DR and 
IgD on both B cell subtypes. The Leu-1  B cells are more brightly staining with 
HLA-DR, but have amounts of IgD comparable to conventional B cells. Fig. 2B 
also illustrates the variable expression of HLA-DR on the Leu-l-bright T  cells. 
Studies  of heavy  chain  expression  showed  that  both  populations  of B  cells 
expressed IgM and IgD but not IgG (data not shown). The Leu-1 B cells stained 
more  brightly  with  anti-IgM  than  did  the  conventional  B  cells.  Both  B  cell 
subtypes  labeled  with  both  anti-K  and  anti-X  in  roughly equal  numbers  (not AULT  ET  AL.  1491 
FIGURE 3.  Analysis of DNA  sequence polymorphisms in patient  151.  DNA preparations 
from patient and donor before marrow transplantation, and free fractionated patient cells on 
days 13,  20, and 64 after transplantation were examined by blot hybridization using probe 
PAW101. DNA from Leu-I B cells (prepared on day 64 as described) is shown in the last lane 
to the right. Patient and donor pretransplant patterns were distinct and easily distinguishable. 
They share a  16 kilobase (kb) allele, but differ at the second locus.  The  14 kb fragment is 
specific for the patient, and the 19 kb fragment is specific for the donor. All posttransplant 
cells show exclusively the donor pattern, and thus were of donor origin. Because of its size, 
the largest fragment (19 kb) is transfered less efficiently in the Southern blot procedure, and 
is only faintly seen in the last two lanes. 
shown).  In  addition,  both  subtypes  expressed  B2  and  Leu-14  in  comparable 
amounts.  Both  labeled very  weakly  or  not  at  all  with  anti-CALLA,  and  were 
Leu-11-. 
DNA  prepared  from  B  cells  of patient  151  was  studied  by  DNA  sequence 
polymorphism  analysis  on  days  13,  20,  and  64.  They  were  also  examined  for 
clonal somatic rearrangement  of the Ig genes on  day 64.  Sorting for the  Leu-1 
B  cells enriched  them  from  18%  to 65%  of total lymphocytes. DNA  from  these 
enriched  cells was  analyzed  with  DNA  from  unsorted  posttransplant  mononu- 
clear cells, pretransplant recipient cells, and donor cells. The  DNA polymorphism 1492  CELL  PHENOTYPING  AFTER  MARROW  TRANSPLANTATION 
analysis demonstrated that there was complete engraftment of donor cells,  and 
that the sorted  Leu-1  B cells  were Of donor origin (Fig.  3).  This analysis can 
detect residual host elements when they comprise as few as  1% of the total (17). 
Thus the Leu-1 B cells did not derive from residual host lymphocytes. Further- 
more,  examination of ]g gene  configuration detected no  evidence for clonal 
somatic rearrangements either before or after transplantation (data not shown). 
Therefore, it is unlikely that they represent either induction of a lymphoprolif- 
erative disorder posttransplantation or transplantation of a preexistent lympho- 
proliferative disorder from the donor. 
NK  Cells.  At least two distinct subtypes of NK cells were identified in all four 
patients. These cells appeared between days 10 and 20 and, taken together, they 
were the most numerous lymphoid cells  present throughout our studies.  Both 
subtypes expressed Leu-11, which was not expressed on either T  cells or B cells. 
Fig. 4A illustrates that the Leu-11 + cells could be separated into those that were 
Leu-2- and those that expressed low levels of Leu-2. These two types are not 
641  A  ~4  B 
,8t 
.  ..~ ~ 
I~  32  48 
Leu-II 
64r  C 
48 
52 
16 
48 
o,# 
i 
-J  :52 
16 
64  48 
',, r:r r~B~?,'l~pV:-,:!  ~:.-'-.'  .sg;:.'( ~'-.-:: ' 
16  ~2 
Leu-7 
h:. !'.  Lllii  '~  _o 
32  ..... _ 
-: ;  ~;TY  ' "  ' 
__  "~;;~-~-I~  ,  ---.  , 
16  3~'  48  6,4  16  3~' 
L Ilu-II  LtU-II 
4'8 
FtGURE  4.  Analysis of  NK  cells  after  transplantation.  (A)  Leu-11  (horizontal)  vs.  Leu-2 
(vertical). The Ts cells that are brightly Leu-2  ÷ are Leu-11-. The population of Leu-1 1  + NK 
cells can be divided into those that express low amounts of Leu-2, and those that are Leu-2-. 
These two populations are not clearly resolved here, but can be clearly seen in other panels. 
(B) Leu-7 (horizontal) vs. Leu-2 (vertical). There is some expression of Leu-7 on Ts cells. The 
majority of the Leu-2-dim cells are Leu-7-, whereas the majority of Leu-7  ÷ cells are Leu-2-. 
(C) Leu-1 1 (horizontal) vs. Leu-7 (vertical). A minority of the Leu-1 1-bearing cells also express 
Leu-7.  (D)  Leu-1 1 (horizontal) vs.  Leu-15  (vertical).  Most of the  NK cells are  Leu-1 1  ÷ and 
Leu-15 +. The cells that are Leu-15 + but Leu-1 1- are primarily T  cells. 
64 
D 
6'4 AULT ET  AL.  1493 
clearly resolved, and thus may not be totally distinct. The Leu-2-dim cells were 
shown above to be clearly Leu-4-, and distinct from Ts. Fig. 4B illustrates that 
the expression of Leu-7 was variable on these cells.  In general, the Leu-2- cells 
seemed to express  more  Leu-7  than  did the  Leu-2-dim cells.  This panel also 
shows  some  expression  of  Leu-7  on  Leu-2-bright  Ts  cells.  Fig.  4C  clearly 
illustrates that the majority of the Leu-7 labeling is on the Leu-11-bearing cells, 
and D shows that all of the Leu-11-bearing cells were Leu-15  ÷.  All of the NK 
cells, both Leu-2- and Leu-2-dim, were characterized by the presence of Leu- 
11,  Leu-15, Leu-5, bright Leu-9, and variable amounts of HLA-DR. They all 
lacked Leu-4, Leu-1, and Leu-3. 
The relative proportions of Leu-2- and Leu-2-dim NK cells varied widely in 
each of our patients. Leu-2-dim NK cells as a percent of total NK cells varied 
from 24 to 79%, with a mean of 52% and a standard deviation of 18%. 
Although the  phenotype of these  cells  is  consistent  with  that  of NK  cells 
defined in normal blood (see  discussion) the designation of these cells  as "NK" 
cells  implies a  functional definition. In  order  to  confirm this,  we  performed 
sorting experiments on cells from patient  151  at a  time when these cells  were 
very numerous (days 30-40).  In  two experiments, we  showed that all  of the 
ability to kill K-562 cells could be recovered in the Leu-11 + population. Sorting 
of the cells into those that were Leu-11 + and either Leu-7  + or Leu-7- showed 
that both the Leu-7  ÷ and Leu-7- cells had equivalent ability to kill.  Similarly, 
sorting ceils  that  were  Leu-i 1  + and either  Leu-2- or  Leu-2-dim showed that 
these two subtypes had equivalent killing activity (data not shown). Thus, these 
cells were "NK" cells by functional criteria, and there were no apparent functional 
distinctions detectable between the subtypes. 
General Observations.  In addition to defining the distinct cell types identified 
above,  our  studies  allow  us  to  make  several  general  statements  concerning 
recovering lymphoid cells after transplantation. The first concerns those antigens 
whose expression we have found to be "variable". These include HLA-DR, Leu- 
7,  Leu-15,  Leu-8, and  Leu-10.  We have  found that each  of these antigens is 
expressed on varying numbers of T  cells during the posttransplant period.  In 
general, the expression of each of these markers is much higher in our transplant 
patients than it is in normal volunteers. This is particularly true for Leu-15 and 
HLA-DR. Further studies will be required to determine the relationships between 
these various markers. 
A second comment must be made about the appearance of Leu-6. Two of our 
patients (153 and 155) had significant numbers of Leu-6-bearing T cells (2-4%). 
Thus,  although  Leu-6-bearing  T  cells  may  be  seen  in  some  posttransplant 
settings, they are not consistently present. The two patients who had detectable 
numbers of Leu-6-bearing cells did not show detectable numbers of cells bearing 
both Leu-2 and Leu-3. 
Quantitative  Analysis  of Cell Types.  Fig. 5 shows the numbers of each of the 
cell types as a  function of time after transplant for patients  151  and  155.  The 
quantitative data for the other two patients are similar. These data have several 
features in common. Most striking is the very large numbers of NK cells  that 
appear  very early.  In  patient  151  at  day 27,  they accounted for 93%  of the 
circulating lymphoid cells.  In patient 155  at day 26, they accounted for 47% of 1494  CELL  PHENOTYPING  AFTER  MARROW  TRANSPLANTATION 
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FIGURE 5.  Recovery of lymphoid cells after transplantation. The time course of recovery of 
the major cell types is shown for the first 90 d after transplantation.  (A), patient  151; (B), 
patient  155. (rn), Th cells; (I), Ts cells; (o), conventional B cells; (o), Leu-1 B cells; (zx), total 
NK cells. The recovery  of all  cell types was more rapid  in  patient  155, who received a 
transplant from an identical twin, but the general features of the cells were the same. In these 
figures, the two types of NK cells described in the text have been combined. 
the lymphoid cells. This is compared with the level of these cells in normal blood, 
ranging from  5  to  15%  (20,  and our unpublished  results).  In addition,  in each 
patient, Ts and Th cells appear early and in roughly comparable numbers.  The 
identical twin, who received marrow that had not been T  cell-depleted, showed 
higher  numbers  of T  cells earlier  than  the  patients  receiving  T  cell-depleted 
marrow. In normal samples, Th cells outnumber Ts by ~2:1,  but this is not the 
case in our posttransplant patients. Third, in three of the patients (151,  153, and 
155),  the appearance of B  cells was delayed to near day 30,  but they then  rose 
rapidly and  became a  predominant  cell type.  Finally,  the  predominance of the 
Leu-1  B  cell  is striking  in  all  three  patients.  Patient  151  first showed  Leu-1  B 
cells at day 30.  Conventional  B cells appeared on day 46, but then decreased in 
numbers,  while  the  Leu-1  B  cells persisted.  Patient  155  first  showed  Leu-1  B 
cells on day 26, and then beginning at day 67 showed a  progressive increase of 
normal B cells. 
Also shown on these figures are data from studies done on the normal donors 
for patients  151  and  155.  The donor for patient  151  has normal proportions of 
NK, Th, and Ts cells.  He appears to be somewhat unusual,  in that he had equal AULT  ET  AL.  1495 
numbers  of conventional  B cells and  Leu-1  B  cells. The  studies on this  donor 
have been repeated twice, with nearly identical results, separated by a period of 
three  months.  Thus,  these  lymphoid cell phenotypes appear  to be stable over 
time in the donor.  The donor for patient  155 also had normal  proportions of 
NK, Th, and Ts cells. The proportion of Leu-I  B cells in this donor was similar 
to what we have observed in other normal volunteers (1-2%). 
Screening for  Chimerism.  Studies  of DNA  sequence  polymorphisms  in  the 
donors and recipients have been carried out in each of the three cases involving 
nontwin donors.  The results, done at several time points following transplanta- 
tion, failed to reveal any evidence for lymphoid chimerism in patients  151  and 
152. Patient  153 did show evidence for mixed iympho-hematopoietic chimerism 
at time points before the appearance of leukemic relapse. Since this method will 
detect residual host cells at levels as low as 1% (17), we can conclude that in two 
of our patients,  all of the cell types we have identified have arisen from donor 
cells. 
Discussion 
The  studies  described here  are  unique  in  their  use of multiparameter  dual 
immunofluorescence analysis and genetic studies to obtain as complete a descrip- 
tion as possible of the recovering lymphoid cell populations after transplantation. 
Previous work on  the  phenotype of recovering  cells began  with  studies  using 
only sheep erythrocyte rosetting to detect T  cells. These studies showed that the 
absolute number and proportion  of T  cells was depressed for a  period of 1-3 
mo (21-26). More recently, several reports (26-31) have appeared showing that 
the early T  cells have a markedly abnormal distribution with regard to "helper" 
and "suppressor" subsets. These results show that "helper" cells remain depressed, 
but suggest that  "suppressor" cells are markedly increased, especially in patients 
with GVHD. Our results suggest that this may be due to confusion between Ts 
cells and Leu-2-bearing NK cells. Previous studies of B cell function have shown 
marked deficiencies in antibody production for a  year or more following trans- 
plantation  (21-25). Despite this, levels of phenotypic B cells returned to normal 
within  1-2 mo (21-24,  32).  Our studies  may shed some light  on this  issue by 
showing that a  large proportion  of the recovering B cells belong to an unusual 
phenotype that may not make normal antibody responses. Elevated levels of NK 
activity  (33)  and  cells,  as judged  by  HNK1  (Leu-7)  labeling  (34)  have  been 
reported in some transplant patients, especially those with chronic GVHD. 
The  major conclusions we have reached  from  these studies on four patients 
are that (a) for the six major lymphoid cell types identified, identical phenotypes 
of recovering cells were seen in each patient; (b) the patients differed only in the 
relative numbers of the various cells types as a function of time, with the identical 
twin transplant recipient making the fastest recovery to near normal proportions 
of cells; (c) the three patients receiving T  cell-depleted marrow differed quan- 
titatively but not qualitatively in the types and  numbers of recovering T  cells, 
when  compared  to the  identical  twin,  who received untreated  marrow;  (d)  T 
cells of the helper and suppressor phenotypes appear in nearly equal numbers 
after transplant;  (e) NK cells are present in strikingly elevated numbers during 
the first 90 d after transplantation;  (f) an unusual phenotype of B cell (the Leu- 1496  CELL  PHENOTYPING  AFTER  MARROW  TRANSPLANTATION 
1  B  cell)  was  identified as  a  major cell  type in  all  three of our patients who 
developed B cells. 
The two patients who were most informative were 151 and 155.  Both of these 
patients had uncomplicated posttransplant courses with no evidence for GVHD 
or overt infection. Thus, we have emphasized the data from these two patients. 
Our  other  two  patients  were  more  complicated in  that  one  (152)  developed 
GVHD, received intravenous anti-T cell mAb therapy, and subsequently died 
of interstitial pneumonitis; the other (153) died of recurrent leukemia. Never- 
theless, these two patients are instructive because there were no striking differ- 
ences  in  recovering  lymphoid cell  types observed  in  these  patients,  with  the 
exception of the absence of B cells in patient 152. Thus, despite the small number 
of patients studied, we feel it is  likely that  the pattern  of lymphoid recovery 
described here is relatively characteristic. Much more extensive studies will be 
necessary  to  determine  whether  quantitative  variations  in  the  phenotype  of 
recovering lymphocytes offer insight into posttransplant complications. Devia- 
tions from the "normal" pattern of reconstitution described here may indicate 
early or subclinical GVHD or viral infection. In addition, failure to observe a 
normal pattern of lymphoid reconstitution may be indicative of partial failure of 
lymphoid engraftment, or of abnormalities of lymphocyte differentiation in some 
recipients. 
Several of the cell types we have observed deserve special comment. All of the 
T  cells in our patients, both Th and Ts, displayed varying amounts of HLA-DR, 
a surface structure thought to represent activation of T  cells  (35).  In addition, 
they displayed variable amounts of several other antigens, including Leu-7, Leu- 
8,  Leu-10, and  Leu-15.  The significance of this fluctuating surface display is 
unknown. It will be important in the future to establish the correlations between 
these various antigens, which we have not done here. They may all reflect various 
states of activation or stages of differentiation of the same cells, or some of them 
may define unique functional subsets, as has been proposed for Leu-15 (12).  It 
is clear that in this setting, Leu-7, which in normal individuals is largely confined 
to non-T NK cells, can be variably expressed on conventional T cells in transplant 
recipients. 
We failed to detect any significant number of T  cells that fit cleanly into the 
category of thymic cells. Only two of our patients showed significant numbers of 
Leu-6-bearing cells, and none had detectable numbers of ceils bearing both Leu- 
2 and Leu-3. There have been previous reports (36) confirming the presence of 
cells expressing T6 (similar to Leu-6); however, the absence of both Leu-2 and 
Leu-3 on these cells  raises a  question as to whether they truly conform to the 
phenotype of early thymocytes. Thus, it seems that if the T  cell population is 
recapitulating  thymic  differentiation  posttransplantation,  the  characteristic 
thymic cells are not circulating. 
The two major types of NK cells  we have identified here, distinguished by 
their expression of Leu-2, are also seen in varying numbers in normal volunteers. 
It may be possible to further subdivide NK cells according to their expression of 
Leu-7, but, since the expression of Leu-7 appeared to be variable on the T  cells, 
we chose not to use it to define further subtypes of NK cells.  The only marker 
we have used that appears to be unique to NK cells is Leu-11, in that we°did not AULT  ET  AL.  1497 
observe  Leu-11  on  T  cells at  any  time.  The  elegant  three-marker  studies  of 
Lanier and Loken (20), using Leu-11, Leu-2, and Leu-7, defined several subsets 
of NK cells in normal blood. A review of their data shows that, in three normal 
individuals,  the  mean  percent  of Leu-11 + NK cells was  9.0%.  Of these,  only 
0.5% also expressed dim Leu-2. Thus, each of our patients not only had markedly 
elevated  numbers  of total  NK  cells,  but also  had  a  marked  disproportionate 
increase  in  Leu-2-dim  NK ceils.  Since  the  Leu-2  molecule can  be released in 
soluble form (37) it remains to be established whether these cells are synthesizing 
their  surface  Leu-2  or  have  passively  acquired  it.  Preliminary  data  in  our 
laboratory suggests that, when cultured in the absence of Leu-2-bearing T  cells, 
these cells continue  to express low levels of Leu-2  for at  least 3  d,  suggesting 
that they are indeed synthesizing the molecule. 
Previous  single-parameter  studies  of post-marrow  transplant  patients  have 
noted a very large number of circulating Leu-2- or T8-bearing cells, which were 
identified as Ts cells (26-31,  38). Our results suggest that  the inclusion of the 
Leu-2-dim population,  which is clearly distinct  from Ts cells, may account for 
these reports.  The  inclusion  of variable numbers of these Leu-2-dim cells may 
also significantly  alter  T4/T8  ratios  calculated  from single-parameter  studies. 
Interestingly, one report (39) of patients with decreased numbers of "suppressor" 
T  cells was carried out with a different marker (TH2). This discrepancy may be 
explained  if the TH2 antibody does not label the  Leu-2-bearing  NK cells (see 
also 31). 
The presence of large numbers of NK cells in the posttransplant setting raises 
the  important  question  of  their  possible  effect  on  hematopoiesis.  There  is 
evidence  in  both  mice  and  man  that  NK  cells  interact  with  hematopoietic 
progenitor cells, and thus may have a  regulatory role.  Hansson et al. (40) have 
reported  that  density  gradient-enriched  human  large  granular  lymphocytes, 
which contain N K activity, are capable of inhibiting granulocyte colony-forming 
units, but have no effect on the development of erythroid burst-forming activity. 
A similar result was recently reported (41) showing an interaction with erythroid 
colony-forming units.  We have recently reported (42) an inhibitory interaction 
between murine NK cells and pluripotent marrow progenitors.  A recent report 
(43) of NK cells bearing both Leu-2 and Leu-15 and mediating suppression of B 
cell  differentiation  adds  the  possibility that  these cells may be responsible for 
some of the B cell defects described above. Our patients have had no evidence 
for defective marrow engraftment,  despite the large numbers of circulating NK 
cells. Thus,  if there is such a regulatory interaction,  it is clearly a  more compli- 
cated issue, requiring further study. 
The final striking  finding in these studies was the presence of large numbers 
of dim Leu- 1-bearing B cells in all three of our patients who developed B cells. 
These cells were characterized in our patients by the presence of relatively large 
amounts of surface IgM and lower amounts of surface IgD. This is in agreement 
with an earlier report (32) of B cells with large amounts of IgM posttransplant. 
This  phenotype of Leu-l-bearing  B  cells is also found in  chronic  lymphocytic 
leukemia; however, examination of these cells from one of our patients failed to 
detect evidence  for clonal  somatic  Ig gene  rearrangements,  and  suggests that 
these cells in our patients are polycional in origin. 1498  CELL  PHENOTYPING  AFTER  MARROW  TRANSPLANTATION 
There  are  several  reports  of similar  cells  in  mice  and  man.  In  mice,  the 
analogous cell type is the Lyt-1 B cell (44, 45). These cells have been described 
in  some  murine  lymphomas,  in  NZB  mice,  and  in  small  numbers  in  normal 
murine  spleens.  There  is  data  implicating  these  cells  in  the  regulation  of Ig 
production by other B cells, and in the production of autoantibodies. They have 
been  shown  to  express  relatively  large  amounts  of surface  IgM,  and  to  be 
responsible for the high levels of spontaneous IgM secretion seen in the autoim- 
mune NZB mice. In man, the Leu-1  B cell has been described in small numbers 
in  normal  individuals  (46),  as  well  as  being  the  characteristic  phenotype  of 
chronic  lymphocytic  leukemia.  We  have  recently  observed  large  numbers  of 
these  cells  in  human  fetal  spleens  (J.  H.  Antin  and  K.  A.  Ault,  unpublished 
observations).  The  role  of these  cells  in  the  human  immune  system  is  still 
unknown, and their significance in the setting of marrow transplantation  will be 
of considerable interest in future investigations. 
Summary 
Four patients who received bone marrow transplants were studied sequentially 
during  the posttransplant  period to define the pattern  of recovering lymphoid 
cell types. Three patients received T  cell-depleted, HLA-matched marrow, and 
one  received  untreated  marrow  from  an  identical  twin.  Blood  lymphoid cells 
were labeled with 25 different pairs of monoclonal antibodies.  In each sample, 
one  antibody  was  conjugated  to  fluorescein  and  one  to  phycoerythrin,  thus 
allowing simultaneous assessment of the expression of the two markers using the 
fluorescence activated cell sorter.  A total of 14 antibodies were used, routinely 
including  HLE,  Leu-M3,  Leu-4,  Leu-1,  Leu-5,  Leu-9,  Leu-6,  Leu-2,  Leu-3, 
HLA-DR, Leu-7,  Leu-11,  Leu-15, and  Leu-12. Other antibodies were used to 
further define some populations. 
This study has allowed us to define six distinct cell types that have appeared 
in all  four patients  by day 90 posttransplantation,  and  which account for  90- 
100%  of all  circulating  lymphoid cells.  These cell types are (a)  T  helper cells 
expressing Leu-1,  Leu-4,  Leu-9,  Leu-5,  Leu-3, and  variable amounts of HLA- 
DR; (b) T  suppressor cells expressing  Leu-1,  Leu-4,  Leu-9,  Leu-5,  Leu-2, and 
variable amounts of HLA-DR; (c) B cells expressing Leu-12, B1, HLA-DR, IgD, 
and IgM, but none of the T  cell antigens; (d) an unusual B cell phenotype (Leu- 
1 B) expressing all of the B cell markers, and also having low amounts of Leu-1, 
but none  of the other  T  cell antigens;  (e) natural  killer  (NK) cells expressing 
Leu-11, Leu-15,  Leu-5 but none of the other T  cell or B cell markers;  (f) NK 
cells expressing Leu-11, Leu-15, Leu-5, and low levels of Leu-2. Both NK types 
also express Leu-7 on some, but not all cells. 
The relative frequencies of these cell types varied among the patients and with 
time, but the striking findings were the presence of relatively few mature T  cells, 
large numbers of NK cells, and the preponderance of the unusual  Leu-1  B cell 
over conventional  B  cells in  all  three  patients  who developed B  cells.  Sorting 
experiments confirmed  the NK activity of the major  NK cell phenotypes, and 
DNA analysis confirmed that  all  of the  cells studied were of donor origin.  In 
addition, analysis of Ig genes in one patient showed that the Leu-1  B cells were 
not clonally rearranged. AULT  ET  AL.  1499 
These dual-parameter immunofluorescence analyses clearly define the pattern 
of lymphoid reconstitution  in these patients, and reveal previously unsuspected 
cell types. They also suggest that depletion of T  cells from donor marrow does 
not drastically alter the pattern of recovery of the immune system. 
We thank the Becton Dickinson Monoclonal Antibody Center, and particularly Dr. Noel 
Warner for contributions of mAb and many helpful discussions. Dr. P.  Leder provided 
the Ig gene probes. We also acknowledge the help of the following persons involved in 
our marrow transplant program: Dr. David G. Nathan, Karen Baker, R. N., Dr. Steven 
J. Burakoff, Dr.  Robert Handin,  Dr. Fred S.  Rosen, Dr. Jeffery Lipton, and the house 
staff and nurses of the Brigham and Women's Hospital and Children's Hospital Medical 
Center. 
Received for publication 24 September  1984 
References 
1.  Oi, V. T., A. N. Glazer, and L. Stryer. 1982. Fluorescent phycobiliprotein conjugates 
for analyses of cells and molecules. J. Cell Biol.  93:981. 
2.  Beverly, P. C. L., D. Linch, and D. Delia.  1980.  The isolation of human haemato- 
poietic progenitor cells using monoclonal antibodies. Nature (Lond.).  287:332. 
3.  Dimitriu-Bona, A., G. R. Burmester, S.J. Waters, and R.J. Winchester. 1983. Human 
mononuclear phagocyte differentiation antigens I. Patterns of antigenic expression 
on the surface of human monocytes and macrophages defined by monoclonal anti- 
bodies. J. lmmunoL  130:145. 
4.  Ledbetter, J.  A.,  A.  E.  Frankel,  L.  A.  Herzenberg, and  L.  A.  Herzenberg.  1981. 
Human  Leu  T  cell  differentiation  antigens:  Quantitative  expression  on  normal 
lymphoid cells and  cell  lines. In  Monoclonai  Antibodies and  T  Cell  Hybridomas, 
Perspectives and Technical Notes. G. Hammerling, U. Hammerling, andJ. Kearney, 
editors. Elsevier/North Holland, N.Y.p.  16. 
5.  Ledbetter, J.  A.,  R.  L.  Evans, M.  Lipinski, C.  Cunningham-Rundles,  R. A.  Good, 
and L. A.  Herzenberg.  1981.  Evolutionary conservation of surface molecules that 
distinguish T  lymphocyte helper/inducer and cytotoxic/suppressor subpopulations in 
mouse and man. J. Exp. Med.  153:310. 
B.  Howard,  F.  D., J.  A.  Ledbetter, J.  Wong,  C.  P.  Bieber,  E.  B.  Stinson,  and  L.  A. 
Herzenberg. 1981. A human T  lymphocyte differentiation marker defined by mon- 
oclonal antibodies that block E rosette formation. J. Immunol.  126:2117. 
7.  Abo, T., and C. M. Balch.  1981. A differentiation antigen of human NK and K cells 
identified by a monoclonal antibody (HNK- 1). J. lmmunol.  127:1024. 
8.  Gatenby, P. A., G. S. Kansas, Y. X. Chen, R. L. Evans, and E. G. Engleman.  1982. 
Dissection of immunoregulatory subpopulations of T  lymphocytes within the helper 
and suppressor lineages in man. J. ImmunoL  129:1997. 
9.  Haynes, B. 1981. Human T lymphocyte antigens as defined by monoclonal antibodies. 
Immunol. Rev. 57:127. 
10.  Chen,  Y.,  R.  L. Evans, M.  S.  Pollack, L.  L.  Lanier, J.  H. Phelps, C. Rousso, N.  L. 
Warner, and F. M. Brodsky. 1984. Characterization of the HLA-DC antigens defined 
by anti-Leu-10. Human Immunol.  10:221. 
11.  Lanier,  L.  L., J.  H.  Phillips,  N.  L.  Warner,  and  G.  F.  Babcock.  1984.  A  human 
natural  killer  cell associated antigen  defined  by monoclonal antibody anti-Leu-11 
(NKP-15): Functional and two-color flow cytometry analysis. J. Leukocyte Biol.  35:11. 
12.  Landay, A., L. Gartland, and A. T. Clement.  1983. Characterization of a phenotyp- 1500  CELL  PHENOTYPING AFTER  MARROW  TRANSPLANTATION 
ically distinct  subpopulation  of Leu-2  + cells  which  suppresses  T  cell  proliferative 
responses. J. Immunol.  131:2757. 
13.  Lampson,  L.  A.,  and  R.  Levy.  1980.  Two populations  of Ia-like molecules on  a 
human B cell line.J. Immunol.  125:393. 
14.  Greaves, M.  F.  1981.  Monoclonal antibodies as probes for leukemic heterogeneity 
and haematopoietic differentiation. In  Leukemia Markers. W.  Knapp, editor.  Aca- 
demic Press, NY. p.  19. 
15.  Stashenko, P., L. M. Nadler, R. Hardy, and S. F. Schlossman. 1980. Characterization 
of a human B lymphocyte specific antigen. J. Immunol.  125:1678. 
16.  Nadler,  L.  M.,  Stashenko,  P.,  R.  Hardy, A. vanAgthoven, C.  Terhorst, and S.  F. 
Schlossman.  198 I. Characterization of a human B cell specific antigen (B2) distinct 
from B1.J. Immunol.  126:1941. 
17.  Ginsburg, D., J.  H. Antin,  B.  R.  Smith,  S.  H.  Orkin, and J.  M.  Rappeport.  1985. 
Origin of cell populations after bone marrow transplantation.  Analysis using DNA 
sequence polymorphisms.J. Clin. Invest.  75:596. 
18.  Korsmeyer, S.J., A. Arnold, A. Bakshi, J. V. Ravetch, U. Seibenlist, P. A. Hieter, S. 
O.  Sharrow,  T.  W.  LeBien, J.  H.  Kersey,  D.  G.  Poplack,  P.  Leder,  and  T.  A. 
Waldmann.  1983.  Immunoglobulin gene rearrangements and  cell surface antigen 
expression in acute lymphocytic leukemias of T  cell and B cell precursor origins. J. 
Clin. Invest.  71:301. 
19.  Ault, K. A., and H. Weiner. 1979. Natural killing of measles-infected cells by human 
lymphocytes. J. Immunol.  122:2611. 
20.  Lanier, L. L., and M. R. Loken, 1984. Human lymphocyte subpopulations identified 
by using three color immunofluorescence and flow cytometry analysis. J.  Immunol. 
132:151. 
21.  Storb,  R.,  H.  D.  Ochs,  P.  L.  Weiden,  and  E.  D.  Thomas.  1976.  Immunological 
reactivity in marrow graft recipients. Transplant Proc.  8:637. 
22.  Elfenbein, G.J., P. N. Anderson, R. L. Humphrey, G. M. Mullins, L. L. Sensenbren- 
ner, J. R. Wands, and G. W. Santos.  1976. Immune system reconstitution following 
allogeneic bone marrow transplantation in man: A  multiparameter analysis. Trans- 
plant. Proc.  8:641. 
23.  Noel, D. R., R. P. Witherspoon, R. Storb, K. Atkinson, K. Doney, E. M. Mickelson, 
H.  D.  Ochs,  R.  P.  Warren,  P.  L.  Weiden,  and  E.  D.  Thomas.  1978.  Does graft- 
versus-host disease influence  the  tempo of immunologic recovery after allogeneic 
human  marrow transplantation?  An observation on  56 long-term survivors. Blood. 
51:1087. 
24.  Gale, R. P., G. Opelz, M.  R. Mickey, P. R. Graze, and A. Saxon.  1978. Immunode- 
ficiency following allogeneic bone marrow transplantation. Transplant. Proc.  10:223. 
25.  Witherspoon, R. P., L. G. Lum, R. Storb, and E. D. Thomas. 1982. In vitro regulation 
of immunoglobulin synthesis after human  marrow transplantation  II. Deficient T 
and  non-T  lymphocyte function  within  3-4  months  of allogeneic,  syngeneic,  or 
autologous marrow grafting for hematologic malignancy. Blood. 59:844. 
26.  Forman,  S. J.,  P.  Nocker,  M.  Gallagher.  1982.  Pattern  of T  cell  reconstitution 
following allogeneic  bone  marrow transplantation  for acute  hematological  malig- 
nancy. Transplantation (Baltimore).  34:96. 
27.  Atkinson, K., J. A.  Hansen, R. Storb, S. Goehle, G. Goldstein, and E.  D. Thomas. 
1982. T cell subpopulations identified by monoclonal antibodies after human marrow 
transplantation. I. Helper-inducer and cytotoxic-suppressor subsets. Blood. 59:1292. 
28.  DeBruin, H. G., A. Astaldi, T. Leupers, R. J. van de Griend, L.J. Dooren, P. T. A. AULT  ET  AL.  1501 
Schellekens, H. J. Tanke, M.  Roos, and J. M.  Vossen.  1981.  T  lymphocyte charac- 
teristics  in  bone  marrow-transplanted patients  II. Analysis with  monoclonal anti- 
bodies.J. Immunol.  127:244. 
29.  Friedrich,  W.,  R. J.  O'Reilly, B.  Koziner, D.  F.  Gebhard,  R.  A.  Good, and  R.  L. 
Evans.  1982. T  lymphocyte reconstitution in recipients of bone marrow transplants 
with and without GVHD: Imbalances of T  cell subpopulations having unique regu- 
latory and cognitive functions. Blood. 59:696. 
30.  Schroff, R. W., R. P. Gale, J. L. Fahey. 1982. Regeneration ofT cell subpopulations 
after bone marrow transplantation: Cytomegalovirus infection and lymphoid subset 
imbalance. J. Immunol.  129:1926. 
31.  Friedrich, W., R. J. O'Reilly, B. Koziner, D. F. Gebhard Jr., R. A. Good, and R. L. 
Evans.  1982. T  lymphocyte reconstitution in recipients of bone marrow transplants 
with and without GVHD: Imbalances of T  cell subpopulations having unique regu- 
latory and cognitive functions. Blood. 59:696. 
32.  Elfenbein, G.J., M. M. Beilis, H. M. Ravlin, and G. W. Santos.  1982. Phenotypically 
immature Bu cells in the peripheral blood after bone marrow grafting in man. Exp. 
Hematol. (NY). 10:551. 
33.  Dokheler, M-C.,J. Wiels, M. Lipinski, C. Tetaud, A. Devergie, E. Gluckman, and T. 
Tursz.  1981.  Natural  killer cell activity in human bone marrow recipients.  Trans- 
plantation  (Baltimore). 31:61. 
34.  Roper, M., J. P. Gockerman, and C. Balch.  1982.  Natural killer (NK) cells in acute 
and chronic graft versus host disease following bone marrow transplantation. Blood. 
60:171a. (Abstr.). 
35.  Hansen, J. A., K. Atkinson, P.J.  Martin, R. Storb, G. Longton, and E. D. Thomas. 
1983.  Human T  lymphocyte phenotype after bone marrow transplantation: T  cells 
expressing I-A-like antigen. Transplantation  (Baltimore). 36:277. 
36.  Rappaport, J. M., M. J. Dunn, and R. Parkman.  1983. Immature T  lymphocytes in 
the peripheral blood of bone marrow transplant recipients.  Transplantation  (Balti- 
more). 36:674. 
37.  Fujimoto, J.,  S.  Levy, and  R.  Levy.  1983.  Spontaneous release of the  Leu-2 (T8) 
molecule from human T  cells.J. Exp. Med. 158:752. 
38.  Linch, D. C., L.J. Knott, R. M. Thomas, P. Harper, A. H. Goldstone, E. G. Davis, 
and R.J.  Levinski.  1983. T  cell regeneration after allogeneic and autologous bone 
marrow transplantation. Brit. J. Haematol. 53:451. 
39.  Reinherz, E. L., R. Parkman, J. Rappaport, F. S. Rosen, and S. F. Schlossman. 1979. 
Aberrations of suppressor T  cells in human graft-vs-host disease. New Engl. J. Med. 
300:1061. 
40.  Hansson, M., M. Beran, B. Andersson, and R. Kiessling.  1982. Inhibition of in vitro 
granulopoiesis by autologous allogeneic human NK cells. J. lmmunol.  129:126. 
41.  Mangan,  K.  F.,  M.  E.  Hartnett,  S.  A.  Matis,  A.  Winkelstein,  and T.  Abo.  1984. 
Natural killer cells suppress human erythroid stem cell proliferation in vitro. Blood. 
63:260. 
42.  Holmberg, L. A.,  B.  A.  Miller, and K. A.  Auk.  1984.  The effect of natural  killer 
cells  on  the  development  of  syngeneic  hematopoietic  progenitors.  J.  lmmunol. 
133:2933. 
43.  Clement, L. T., C. E. Grossi, and G. L. Gartland.  1984. Morphologic and phenotypic 
features of the subpopulation of Leu-2  + cells that suppress B cell differentiation. J. 
Immunol.  133:2461. 
44.  Hayakawa, K., R. R.  Hardy, D.  R. Parks, and L. A. Herzenberg.  1983. The "Ly-1 1502  CELL  PHENOTYPING AFTER  MARROW TRANSPLANTATION 
B" cell subpopulation in normal, immunodefective, and autoimmune mice. J.  Exp. 
Med.  157:202. 
45.  Hayakawa, K., R. R. Hardy, M.  Honda, L. A. Herzenberg, A. D. Steinberg, and L. 
A.  Herzenberg.  1984.  Ly-1  B  cells:  Functionally distinct  lymphocytes that secrete 
IgM autoantibodies. Proc. Natl. Acad. Sci. USA.  81:2494. 
46.  Caligaris-Cappio, F.,  M. Gobbi, M. Bofilt,  and G. Janossy.  1982.  Infrequent normal 
B  lymphocytes express  features  of B-chronic  lymphocytic leukemia. J.  Exp.  Med. 
155:623. 